English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Psilocybe Azurescens: The Most Potent Magic Mushroom and How It's Grown
If you've spent any time reading about psychedelic mushrooms, you've probably bumped into the name Psilocybe azurescens — usually wrapped in superlatives. The strongest. The wildest. The one that grows in the dunes. Most of that hype is actually true, which is rare for a corner of the plant-medicine world that loves a tall tale. Azurescens is a genuinely remarkable little mushroom with a short, strange history and a personality of its own. This is a closer look at where it came from, why it punches so hard, and what's involved if you ever wanted to grow it — written for the curious reader, not the commercial cultivator. Whether you're researching psilocybin out of personal interest or weighing it as part of a broader interest in psychedelics and master plants, knowing the basics about this species is worth your time. Azurescens is a wood-loving species native to a slim stretch of the Pacific Northwest coast in the United States — think the Oregon and Washington shoreline, where conifer debris, dune grass, and damp salt air meet. It's a relative newcomer to mycology. The species was formally described in 1996 by Paul Stamets and Jochen Gartz, after being noticed years earlier by a group of Boy Scouts camping near the mouth of the Columbia River. The story goes that one of them was Stamets' son. Whether that origin tale is fully accurate or partly folklore, the mushroom got its scientific name and its nickname — “Flying Saucer Mushroom,” for the wavy, UFO-shaped caps it produces in cool weather. What sets azurescens apart isn't its looks, though. It's the chemistry. By dry weight, this species contains some of the highest concentrations of psilocybin, psilocin, and baeocystin ever measured in a wild mushroom. Roughly speaking, it tests at around three times the potency of the more familiar Psilocybe cubensis — the species behind nearly every store-bought grow kit and most underground supply. That fact alone is responsible for a lot of azurescens' reputation, and a lot of trouble for the unprepared. Caramel-brown caps that flatten out and develop a slight nipple in the centre. A whitish stem that bruises a vivid blue-green when handled — the classic signature of psilocybin-bearing species. Dark purple-brown spores. It tends to fruit in clusters on woody debris, often hidden under dune grass, between September and January when temperatures drop into single digits Celsius. Cold is part of its lifestyle, not an obstacle to it. Three times the strength of cubensis is not a marketing line — it's a practical warning. A dose of dried azurescens that would fit on a teaspoon can produce an experience that, with cubensis, would require a small handful. People accustomed to gauging mushroom doses by volume rather than weight have learned this the hard way. Reports of temporary paralysis at higher doses of azurescens circulate widely in mycology forums, and while the phenomenon isn't fully understood, it appears often enough that it deserves to be taken seriously. Beyond raw intensity, the experience is frequently described as more visual, more “alien,” and harder to steer than a comparable journey on cubensis. Whether that's pharmacology or expectation effect is up for debate. What isn't debatable is that this is not a beginner mushroom, and nobody should be approaching it as a casual weekend experiment. If you're newer to psilocybin and curious about the deeper end of the experience, a properly guided ceremony in a country where it's legal — Netherlands, Jamaica, certain parts of the U.S. — is a far safer doorway than a dune walk on the Oregon coast. People hear “most potent mushroom in the world” and immediately want to grow it. Understandable. The reality is that azurescens is one of the more demanding species in the genus to cultivate, and it doesn't reward shortcuts. Unlike cubensis, which colonises grain and fruits indoors on a rye-cake at room temperature in a few weeks, azurescens wants what it has in the wild: wood, cold, and patience. Here's the short version of how outdoor cultivation typically works: Indoor attempts using terrariums and refrigerated fruiting chambers exist, but the consensus among experienced cultivators is that azurescens is fundamentally an outdoor species. Trying to force it indoors usually means a long wait followed by disappointment. This is the part nobody likes. Psilocybin remains a controlled substance in most of the world, including the United States — yes, even though azurescens grows wild there. Cultivation, possession, and distribution carry real legal consequences in most jurisdictions. A small number of places have decriminalised personal use (Oregon, parts of Colorado, the Netherlands' truffle loophole), but “decriminalised” and “legal” are not the same thing, and the picture changes constantly. Before doing anything, check the law in your actual location, not the one you wish you lived in. There's a tendency in psychedelic circles to chase potency — to assume that stronger means better, deeper, more transformative. It doesn't. Some of the most useful psilocybin experiences happen at moderate doses with capable guides, in settings designed for integration. The reason a species like azurescens fascinates so many people isn't really about the milligram count. It's the romance of the wild — a powerful master plant fruiting on a windy beach in the rain, indifferent to anyone's intentions for it. If that romance is what's drawing you, it's worth asking what you actually want. Self-knowledge? Help with a stuck depression or an addiction pattern? Curiosity about consciousness? Each of those goals points toward different settings and different medicines. Ayahuasca ceremonies in the Peruvian Amazon, ibogaine programmes for opioid dependency, psilocybin retreats in Jamaica or the Netherlands — these are structured environments with people whose job is to keep you safe and help you make sense of what comes up. A wild-foraged batch of the world's strongest mushroom is the opposite of that. Plant medicines work best when you bring them context. Set, setting, and integration aren't buzzwords; they're the difference between an experience that reshapes your year and one that just shakes you. For readers who want to take this curiosity further in a held container rather than a solo experiment, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever path you choose, choose it with both eyes open — these mushrooms have been doing this far longer than we have, and they deserve some respect.
One Psychedelic Trip, Lasting Change: What the Research Actually Suggests
Ask anyone who has sat through a full ayahuasca night, or watched the geometry behind their closed eyes during a high-dose psilocybin session, and they'll usually tell you the same thing. Something shifted. Not in the way a good holiday shifts you for a fortnight before the inbox swallows everything again — something deeper, stranger, more permanent. For years that claim lived in the realm of anecdote, traded between facilitators and integration circles. Now the research is starting to catch up, and the picture it paints is genuinely striking: a single psychedelic experience, taken seriously, can leave fingerprints on a person's mental health and worldview for decades. One of the more talked-about studies on this question came out of the Johns Hopkins University School of Medicine in Baltimore — a team that's been doing some of the most careful work on psychedelics, plant medicine, and the so-called mystical experience for the better part of twenty years. Their large-scale survey compared what people describe after taking psilocybin, LSD, DMT, and ayahuasca with what people describe after similar encounters that happened without any substance at all. The findings are worth sitting with, especially if you're someone weighing whether to book a retreat. The researchers gathered reports from thousands of people — over a thousand each for psilocybin and LSD, hundreds more for DMT and ayahuasca, plus a non-drug control group of around eight hundred who'd had similar encounters spontaneously through meditation, prayer, near-death experiences, or just out of nowhere on a Tuesday afternoon. Participants described what the team called God encounter experiences, which is loaded language, but the underlying phenomenon is broader than the word suggests: a sense of contact with something the person experienced as ultimate reality, intelligence, or presence. Here's the part that tends to get repeated, and deservedly so. Roughly two-thirds of participants who identified as atheists before the experience no longer did afterward. Not because someone preached at them. Not because they joined a church. Because something happened during the experience that they could no longer square with the worldview they walked in with. And — this is the bit that matters for retreat-seekers — most of them reported lasting positive changes in life satisfaction, sense of purpose, and mental health that they directly attributed to that single encounter. Roland Griffiths, who led the work before his passing, made a point that's easy to miss. Western medicine, he noted, doesn't usually count spiritual or religious experiences as therapeutic tools. The data suggest maybe it should. These encounters keep correlating with improvements in mental health, sometimes years after the fact, sometimes after just one session. This is the question that haunts anyone who's spent serious time and money in talk therapy without getting the traction they hoped for. How does one night with a brew, or one afternoon with a capsule, do something that fifty sessions on a couch couldn't? The honest answer is that nobody fully knows yet. But there are some reasonable hypotheses, and they fit what facilitators in the ayahuasca world have been saying for generations. Psychedelics seem to do at least three things at once. They temporarily loosen the brain's habitual patterns — the default-mode network goes quiet, and the rigid stories you tell yourself about who you are get a brief sabbatical. They make emotional material accessible that's usually walled off. And they often produce that sense of meaningful encounter, whether you'd call it spiritual or just deeply significant, which seems to act as a kind of psychological anchor for the changes that follow. Put plainly: you don't just think something new about your life. You feel something new, somewhere underneath thinking, and the feeling is vivid enough that it doesn't fade the way an insight from a self-help book fades by Wednesday. If you're reading this because you're researching whether to book an ayahuasca retreat, a psilocybin journey, or an ibogaine programme for addiction, the research is encouraging but it isn't a guarantee. A few honest things worth knowing: The studies also keep finding that people who go in with a clear intention — working with depression, addiction, grief, a stuck pattern — tend to report the most useful outcomes. Tourists looking for novelty get novelty. People looking for a reckoning often get one. Something the survey doesn't quite capture is the difference between, say, taking LSD with a trusted friend in a quiet flat and drinking ayahuasca with a curandero who's been working with the brew for thirty years. Both can produce profound experiences. The traditions around the master plants — ayahuasca, San Pedro, peyote, iboga — add a layer of context that pharmaceutical psychedelics generally don't. There's diet, dieta, song, ritual, lineage. Whether you find that essential or beside the point depends on temperament, but it does seem to shape how people make sense of what happens to them, and meaning-making is most of the game in psychedelic healing. This is also where the addiction-recovery story gets interesting. Ibogaine in particular has a striking track record with opiate dependency, and ayahuasca has been showing up in studies on alcohol and stimulant addiction. The mechanism isn't just chemical — these substances seem to give people a vantage point from which their addiction looks different, smaller, more workable. That's not a cure on its own. But for many it's the opening that years of conventional treatment couldn't make. If you're seriously considering this path, slow down. Read more than one source. Talk to people who've done it. Ask a retreat about their screening process, their facilitators' lineage and training, what aftercare looks like, what happens if someone has a medical emergency, how they handle psychological difficulty in the room. Reputable places welcome these questions. The ones that don't are telling you something. Budget for integration as seriously as you budget for the retreat itself. The week of ceremony is the spark. The six months that follow are where the actual life change happens or doesn't. Therapists trained in psychedelic integration are becoming easier to find, and integration circles — often free or donation-based — are worth their weight in gold. The research, taken together, is doing something quietly revolutionary: it's giving people permission to take seriously what plant-medicine cultures have known for centuries. That a properly held encounter with these substances isn't recreational, and it isn't only medical either. It's something older and stranger, and for the right person at the right moment, it can rearrange a life. If any of this resonates with where you are right now, a curated range of ayahuasca and psychedelic retreats can be browsed on our marketplace here — worth a look if you want to see what's actually out there rather than guessing.
Psychedelics as Medicine: What Science Actually Says About MDMA, Psilocybin, and Ketamine
Something genuinely strange is happening in medicine. Substances that landed people in jail a generation ago are now sitting in clinical trial pipelines, getting fast-tracked by regulators, and inspiring the kind of investor enthusiasm usually reserved for tech IPOs. If you've been quietly wondering whether psychedelics might help with depression, addiction, or trauma that hasn't budged in years — you are not imagining the shift. The science has been catching up to what indigenous traditions and a handful of stubborn researchers have been saying for decades. But the headlines run hot, and most retreat-seekers I talk to are not looking for hype. They want to know what's actually working, what's still experimental, and how any of it connects to the very real question of whether to fly to Peru, Costa Rica, or the Netherlands and sit in a ceremony. So here's the honest map — what current research suggests about MDMA, psilocybin, ketamine, and ayahuasca, and how that intersects with the world of plant medicine retreats. For roughly forty years after the cultural backlash of the late 1960s, serious psychedelic research basically stopped. Funding dried up. Careers were quietly ended. Then, around the early 2000s, a few research groups — Johns Hopkins, Imperial College London, NYU, MAPS — started getting permission to study these compounds again. The early results were strong enough that the conversation has, slowly, gone mainstream. What's driving the resurgence isn't just curiosity. It's that conventional psychiatry has hit a wall. SSRIs help some people some of the time. Talk therapy is essential but slow. Treatment-resistant depression, complex PTSD, end-of-life anxiety, and entrenched addiction remain stubborn problems that swallow lives. Psychedelics — for all their cultural baggage — appear to do something genuinely different at the neurological level. They appear to loosen the brain's habitual patterns in a way that lets people see their lives, and their pain, from outside the rut. This is the same territory that traditional plant medicine has worked with for centuries. The vocabulary is different. The framing is different. The underlying phenomenon may not be. Of all the psychedelic-adjacent compounds in research, MDMA has gone the furthest down the regulatory road. Studies running through MAPS (the Multidisciplinary Association for Psychedelic Studies) showed striking results — in some trials, around two-thirds to three-quarters of participants with chronic, treatment-resistant PTSD no longer met the diagnostic criteria after a course of MDMA-assisted therapy. These were people who had been suffering, in many cases, for over a decade. The mechanism makes intuitive sense to anyone who has done trauma work. MDMA temporarily quiets the fear response while keeping the patient lucid and able to talk. Combat veterans, sexual assault survivors, and first responders have described being able to revisit memories that, sober, were simply too overwhelming to approach. The therapy isn't the drug — it's the trauma processing that the drug makes possible. It's not risk-free. MDMA raises blood pressure and body temperature, can cause insomnia for days afterwards, and is genuinely dangerous outside a medical setting where dose and purity are controlled. Recreational ecstasy is not the same thing as a measured dose in a clinical room with two therapists present. That distinction matters. Researchers studying psilocybin — the active compound in magic mushrooms — have used phrases like "surgical intervention" to describe what a single high dose, in the right setting, can do to depression. That's not marketing language. It comes from clinicians watching cancer patients with crushing end-of-life anxiety report durable shifts in mood and outlook after one or two sessions. Brain imaging gives a partial explanation. Depression seems to involve over-activity in the brain's default mode network — the circuit that runs rumination, self-criticism, and the looping replay of regrets. Psilocybin appears to temporarily dial that network down, which is part of why people describe a sense of "ego dissolution" during the experience. When the ego comes back online a few hours later, the grooves it ran in seem, for a while, less deep. A handful of well-funded biotech companies are now running large psilocybin trials for treatment-resistant depression. The serious researchers in the field believe a psilocybin-based prescription medicine could be approved before the end of this decade. In the meantime, psilocybin retreats have opened legally in the Netherlands (where truffles remain legal), Jamaica, and a growing number of jurisdictions in the Americas. Ketamine is the odd one out — technically a dissociative anesthetic rather than a classical psychedelic, but its rapid antidepressant effects have been hard to ignore. A nasal spray version called Spravato has been an approved depression treatment in the United States for several years now, specifically for severe depression that hasn't responded to other medications. What's notable about ketamine is the speed. Conventional antidepressants can take six weeks to do anything. Ketamine can lift suicidal ideation within hours. That's a different category of intervention — closer to emergency medicine than to maintenance therapy. The mechanism involves a brain receptor system (the NMDA pathway) that older antidepressants largely ignored. Ketamine clinics have proliferated quickly, which is both encouraging and worth approaching carefully. The quality of the integration and therapeutic container varies wildly. A ketamine infusion in a strip-mall clinic with no follow-up support is a different experience from ketamine-assisted psychotherapy with a skilled practitioner. Ayahuasca hasn't gone through the same Western regulatory pipeline as MDMA or psilocybin, partly because it's a brew rather than a pharmaceutical molecule, and partly because its cultural home is in indigenous Amazonian practice rather than a lab. But early research — much of it coming from Brazilian institutions and observational studies of long-term churchgoers in syncretic traditions like Santo Daime and the UDV — points in directions that align with what's being seen for psilocybin. Reductions in depression and anxiety scores. Shifts in addictive patterns. A common report of having been shown something true about one's own life. Ayahuasca contains DMT, which is structurally similar to psilocybin and serotonin, alongside MAO inhibitors from the caapi vine that allow it to work orally. The pharmacology is real. The ceremonial container, in traditional settings, is what allows the pharmacology to land therapeutically. This is the piece that gets lost in the rush to medicalize. The drug is part of the medicine. The space, the music, the facilitator, the dieta beforehand, and the integration afterwards are the rest of it. A retreat done well bundles those elements; a retreat done poorly hands you a cup of brew and hopes for the best. Reading the research can make you feel like the answer is obvious — book a retreat, fix the depression, change your life. The reality is more textured. A few things worth holding in mind: The research is real and it's promising. It is not a guarantee, and it does not replace the slow work of becoming a different person. What psychedelics — in clinical settings or in traditional ceremony — seem to offer is an opening. A few hours in which the usual self loosens its grip enough that something new can be glimpsed. Whether that glimpse becomes a life depends on what gets built around it. If you're somewhere on the spectrum from curious to quietly desperate, treat the decision the way you'd treat any other significant medical and personal choice. Read widely. Talk to people who've actually sat. Vet facilitators carefully. Take the preparation and the aftercare as seriously as the ceremony itself. For readers who want to take this further, a range of vetted ayahuasca and plant medicine retreats can be browsed on our marketplace here, with details on facilitators, traditions, and the kind of work each container is designed for.
Psychedelics for Depression and Addiction: What the Research Actually Shows
Picture a quiet room in Manhattan. A low brown couch, a small Buddha statue, hand-painted dishes on a side table. It looks like someone's grandmother's living room from 1974. It is, in fact, the setting where some of the most surprising mental-health research of the last decade has unfolded — a place where cancer patients have swallowed a capsule of psilocybin and walked out hours later describing the experience as one of the most meaningful of their lives. This is the strange, hopeful frontier of psychedelics and psychedelic-assisted therapy. After decades of being treated as cultural contraband, substances like psilocybin, ayahuasca, ibogaine, and MDMA are being studied seriously again — and the early data on depression, anxiety, and addiction is hard to ignore. If you've found your way here because you're quietly wondering whether plant medicine might help with something you've been carrying for years, you're not alone. A lot of people are wondering the same thing. The reason scientists keep using words like “breakthrough” and even “surgical intervention” when they talk about psychedelics isn't hype. It's that a single dose, given in the right setting with trained support, seems to do what years of daily SSRIs sometimes can't — particularly for people stuck in the deepest grooves of despair. In one well-known trial at NYU and Johns Hopkins, cancer patients with severe end-of-life anxiety were given psilocybin alongside therapy. The majority reported sustained relief from depression and existential dread months later. Not a slight improvement. A genuine shift. Many of them ranked the experience among the top five most meaningful events of their entire lives — comparable to the birth of a child or the death of a parent. That's an unusual thing to hear from a clinical trial. Pharma research doesn't usually produce results that read like a memoir. Here's a way to think about depression that helped me understand why psychedelics seem to do what they do. Imagine your brain as a city, full of roads. Some are well-worn highways used a thousand times a day — your habitual thoughts, your self-criticism, your story about why you're not enough. Other roads are barely paved, rarely traveled. In a depressed brain, the highway traffic gets stuck. Rush hour, all day, every day. Researchers at Imperial College London have shown that psychedelics appear to do something genuinely strange — they reduce traffic on the overused routes and send neural activity skittering down the empty ones. Connections form between regions of the brain that normally don't talk to each other. The cogs, as one researcher put it, get loosened. That loosening is often what people describe afterward. The rumination quiets. The sense of being trapped inside one narrow story about yourself softens. For a few hours, the mind escapes the rut — and sometimes, the new perspective sticks. The addiction research is where things get especially interesting. Addiction, like depression, is partly a story of stuck patterns — the same circuits firing, the same craving, the same coping behavior on repeat. Substances like ayahuasca, ibogaine, and psilocybin appear to interrupt those loops, sometimes dramatically. Ibogaine, derived from the iboga root of West Africa, has the longest underground reputation for treating opioid dependence. People who've gone through ibogaine treatment often describe a long, difficult inner journey — sometimes 24 to 36 hours of intense visions — followed by a striking reduction in withdrawal symptoms and cravings. It's not magic, and it's not without serious cardiac risks that require medical screening. But for people who've tried everything else, it's often the first thing that's actually worked. Ayahuasca, the Amazonian brew built around the Banisteriopsis caapi vine, has a different shape but a similar effect on certain people. The ceremonies are long, communal, and held by experienced facilitators in traditions that stretch back generations. Many participants come specifically because of addiction — to alcohol, to cocaine, to the quieter addictions of overwork and self-loathing — and leave with a fundamentally different relationship to whatever they were running from. The category of plants and brews used this way is sometimes called the master plants: teachers in the Amazonian sense, not chemicals to be consumed casually. That framing matters, because it shapes how the experience is approached — with preparation, respect, and a willingness to actually listen to what surfaces. This is the question almost everyone researching a retreat wants answered honestly, so let's be honest. A psychedelic ceremony — whether it involves ayahuasca, psilocybin, or San Pedro — is not a euphoric night out. It can be uncomfortable. It can be physically demanding. With ayahuasca specifically, vomiting (called la purga) is common and considered part of the healing. People often describe an initial wave of fear or disorientation. One man I spoke with, a sailor who'd done a Johns Hopkins psilocybin trial, compared the early part of his experience to falling off his boat in open ocean — looking back and finding the boat gone, then the water gone, then himself gone. Terrifying, in the moment. He came through it, with help from his facilitators, into something he still can't quite describe — a sense of being witness to life itself, free from the constant management of being a self. That arc — through difficulty, into something larger — is common. It's why a good retreat isn't just about the medicine. It's about who's holding the space. If you're considering a retreat, this is where to spend your attention. The medicine matters less than the container around it. Here's what experienced facilitators and seasoned participants tend to look for: One more thing: be skeptical of anyone who promises outcomes. Real facilitators talk about possibilities and risks. Sales pitches talk about transformation guaranteed. It depends entirely on where you are and what plant you're talking about. In the United States, psilocybin is federally illegal but decriminalized in cities like Denver, Oakland, and parts of Oregon, where supervised therapeutic use is now permitted under state law. Ayahuasca is federally illegal except for specific religious exemptions granted to the União do Vegetal and Santo Daime churches under a 2006 Supreme Court ruling. Outside the U.S., the landscape opens up. Peru, Costa Rica, the Netherlands, Jamaica, Mexico, and Brazil each host legal or tolerated retreat scenes for various plant medicines. Most serious retreat-seekers end up traveling, both for legal reasons and because the lineages are stronger where the plants come from. Plant medicine isn't for everyone. People with personal or family histories of schizophrenia, bipolar disorder, or psychotic episodes are generally advised to avoid classical psychedelics. Certain heart conditions rule out ibogaine. SSRI users typically need to taper off well before drinking ayahuasca, under medical guidance. And then there's the harder caveat: a single ceremony, no matter how profound, isn't a cure. It's a doorway. Whatever you see inside still has to be carried back into your daily life — your relationships, your work, your habits. The people who get the most lasting benefit are almost always the ones who do the integration work afterward, often with a therapist who understands psychedelics. For readers who want to take this further, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, take your time with the decision — this is one of those choices that rewards patience and punishes impulse.
Mushrooms and Brain Health: Can Psilocybin and Functional Fungi Help Prevent Alzheimer's?
Watching a parent forget your name is a particular kind of grief. It arrives in pieces, over years, and by the time you understand what's happening, the person you knew has already started to fade. For families with a history of Alzheimer's, that grief tends to carry a second weight — the quiet question of whether the same thing is waiting for them. That question is fueling one of the more interesting corners of the current psychedelic and plant medicine conversation: the role of mushrooms — both the functional kind like Lion's Mane and the psychedelic kind like psilocybin — in supporting long-term brain health. It's a thread that runs from cutting-edge neuroscience labs to grandmothers microdosing in suburban kitchens, and it's worth pulling on if you're someone trying to protect your mind for the decades ahead. The standard medical answer to Alzheimer's has, for decades, been a shrug dressed up in a lab coat. A few drugs slow symptoms modestly. None reverse the disease. And the cruel structural problem is this: by the time symptoms appear, the underlying damage has been building quietly for twenty or thirty years. If you want to do something useful, you have to start long before anything feels wrong. That timeline is what's pushed a lot of curious, science-literate people toward mushrooms. Functional varieties — Lion's Mane, reishi, cordyceps, chaga — have been used in East Asian medicine for centuries. Lion's Mane in particular has caught researchers' attention because of compounds called hericenones and erinacines, which appear to stimulate nerve growth factor in the brain. In plain English: they may help neurons grow and stay connected. That's exactly the machinery Alzheimer's destroys. Then there are the psychedelic mushrooms, which work on a different but related axis. Psilocybin, the active compound in magic mushrooms, has been shown in early studies to promote neuroplasticity — the brain's ability to rewire itself and form new connections. Researchers at Johns Hopkins and Imperial College London have spent the past several years documenting how a single high dose can reset patterns of depression that have resisted every other treatment. The implications for cognitive aging are still being studied, but the early signals are interesting enough that serious money and serious scientists are paying attention. This trips people up, so it's worth being clear. Not all medicinal mushrooms get you high. In fact, most don't. Both categories are mushrooms. Both are being studied for brain benefits. But they work through very different mechanisms and demand very different commitments from the person taking them. Functional mushrooms are a daily habit, like a vitamin. Psychedelic mushrooms — taken at ceremony doses — are an event you prepare for, integrate from, and don't take lightly. Microdosing has gone from Silicon Valley curiosity to something your aunt might be doing. The basic idea: take a sub-perceptual dose of psilocybin (usually around a tenth of a recreational dose) on a schedule — say, every third day for a few weeks — and observe what happens. People report sharper focus, lifted mood, reduced anxiety, and a softer relationship to old mental ruts. Veterans use it for PTSD. Mothers use it for the relentless cognitive load of parenting. Older adults are starting to use it specifically with brain longevity in mind. The research here is genuinely early. Placebo effects are real, dosing isn't standardized, and most of what we know comes from self-reports rather than controlled trials. That said, the consistency of those reports across very different populations is hard to dismiss entirely. Companies and academic labs are now running proper studies to figure out what's signal and what's noise. If you're considering microdosing, a few honest cautions: legality varies wildly by where you live, dosing without scales and proper sourcing is a recipe for inconsistent experiences, and microdosing isn't appropriate for people with certain mental health conditions or on certain medications. It is not a magic bullet. It is, at best, one tool in a much larger toolkit. Here's the part the supplement industry would prefer you skip. Mushrooms — functional or psychedelic — are not going to save a brain that's being neglected in every other way. The boring stuff still matters more than anything in a capsule. Mushrooms slot into this picture as a possible enhancer, not a replacement. The person taking Lion's Mane while sleeping four hours a night and living on takeout is not going to outrun their genetics. For some people, the entry point isn't a daily supplement but a single, carefully held psychedelic experience — often within the container of a retreat. Psilocybin retreats in legal jurisdictions like the Netherlands, Jamaica, and increasingly parts of the U.S. offer multi-day programs where participants prepare, journey under supervision, and integrate what came up afterward. Ayahuasca retreats in Peru, Costa Rica, and elsewhere offer something related but distinct — a longer, often more challenging plant medicine arc with deep indigenous roots. Why would someone worried about Alzheimer's consider this? A few reasons. The neuroplasticity window opened by a full psychedelic experience appears to last weeks, not hours. The psychological work that often happens — releasing long-held grief, untangling patterns of depression, reconnecting with purpose — has its own protective effect on the aging brain. And for people with a strong family history, the experience of facing mortality directly, which most ceremonies provoke in one form or another, tends to clarify priorities in ways that change everyday behavior. None of this is a guarantee. Retreats vary enormously in quality, screening, and safety, and the wrong setting can do more harm than good. If you're exploring this path, vet facilitators carefully, be honest about medications and medical history, and pay attention to whether the program treats integration as seriously as the ceremony itself. For readers who want to explore this further, curated psilocybin and plant medicine retreats can be browsed on our marketplace here. The science of mushrooms and brain health is real, promising, and nowhere near settled. Lion's Mane and other functional mushrooms have a plausible mechanism and a long traditional track record. Psilocybin has produced some of the most striking results in modern psychiatry. Microdosing is interesting and under-studied. None of it is a substitute for sleep, movement, diet, and human connection — and none of it can rewind damage that's already done. But for someone in their thirties, forties, or fifties watching a parent disappear into Alzheimer's, the question isn't whether mushrooms are a miracle. It's whether the accumulated weight of small, intelligent choices made over decades can shift the odds. The current evidence says yes, probably, and that fungi — humble, ancient, and increasingly well-studied — deserve a real seat at that table.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Psilocybin Therapy in Oregon: What Legal Access Actually Looks Like
A few years back, the idea of legally sitting with psilocybin mushrooms — in a licensed space, with a trained facilitator, without breaking any laws — sounded like wishful thinking. Then Oregon happened. In November 2020, voters there passed Measure 109, and the state became the first in the U.S. to create a regulated framework for supervised psilocybin use. The rollout has been slow, messy, and fascinating. And if you're someone weighing whether psychedelics might help with depression, trauma, or just a stuck patch of life, what's unfolded in Oregon matters. This isn't a political post. It's a practical one. I want to walk through what Oregon actually legalized, how it fits into the broader psychedelic renaissance, where it leaves people who can't fly to Portland, and what to keep in mind if you're considering plant medicine or psilocybin in a retreat setting. There's a lot of hype out there. The reality is more interesting — and more nuanced — than the headlines suggest. Here's the short version. Measure 109 didn't make psilocybin legal in the way alcohol or cannabis is legal in some states. You can't walk into a dispensary and buy dried mushrooms. You can't grow them at home for personal use without risk. What the measure created was a tightly controlled service model: licensed facilitators, licensed service centers, and clients who go through a preparation session, a dosing session, and an integration session — all on-site, all supervised. You don't need a diagnosis to participate. That's a meaningful detail. Unlike most clinical trials, where you have to qualify with treatment-resistant depression or end-of-life anxiety, Oregon's framework treats psilocybin services as a wellness offering open to adults. Whether that's a feature or a bug depends on who you ask. The state's Psilocybin Services program took its time to write the rules. The first licensed service centers opened in 2023, and as of 2026 there's a working — if still small — network of providers across the state. Prices for a full session run from about $1,500 to $3,500, sometimes more, which is a real barrier and one of the loudest criticisms from advocates who pushed for decriminalization instead of (or alongside) legalization. Oregon didn't happen in a vacuum. For years, researchers at Johns Hopkins, NYU, Imperial College London, and elsewhere have been publishing studies showing that psilocybin — given in a supportive setting, with proper preparation — can produce striking reductions in depression and anxiety, including in people who haven't responded to conventional treatment. The cancer-patient studies got the most press, but the work on major depression and on alcohol-use disorder has been just as compelling. That research is what cracked the door open. Decriminalization measures in Denver, Oakland, Santa Cruz, Ann Arbor, and a growing list of other cities pushed it open further. Then Oregon legalized supervised access. Colorado followed with Proposition 122 in 2022, which created its own regulated framework plus broader decriminalization of several plant medicines, including DMT and mescaline. The picture across the U.S. is now a patchwork. Federally, psilocybin remains a Schedule I substance. State by state, city by city, the rules shift. If you're researching options, the legal landscape where you live is worth checking carefully — not because anyone's likely to kick down your door, but because where the law sits affects which providers operate openly, what kind of training they've had, and what recourse you have if something goes wrong. People imagine a lot of things when they hear “legal mushroom therapy.” The reality is quieter than the imagination. A typical session at an Oregon service center looks something like this: It's not a party. It's not a quick fix. People who walk in expecting fireworks sometimes leave underwhelmed; people who walk in with humility and a real question often leave changed. Your experience depends on dose, set, setting, and frankly your nervous system on the day. The medicine doesn't perform on demand. If you're researching psychedelic options seriously, you've probably noticed that psilocybin isn't the only path on the table. Ayahuasca retreats in Peru, Costa Rica, and increasingly in legally permissive corners of Europe; ibogaine clinics in Mexico for people working through opioid addiction; San Pedro and huachuma ceremonies in the Andes; psilocybin retreats in Jamaica, the Netherlands, and now Oregon. Each tradition carries its own culture, its own risks, its own kind of work. Psilocybin tends to be the gentler doorway. The experience is usually shorter, the body load lighter, the integration arc more manageable for first-timers. Ayahuasca is longer, more physical (yes, the purging is real), and rooted in lineages worth understanding before you sign up. Ibogaine is a different animal entirely — powerful for addiction interruption, but with real cardiac risks that require medical screening. The point isn't to rank them. The point is that the choice should match what you're actually working on. Someone navigating grief and mild depression might find a supervised psilocybin session to be exactly the right size. Someone wrestling with deep generational trauma or long-term substance dependence might be better served by a longer-format plant-medicine retreat with experienced facilitators. There's no universal answer here. Whether you end up booking a psilocybin session in Oregon, an ayahuasca retreat in the Sacred Valley, or something else, the same questions apply. The legal status of a place is one signal. It's not the only signal, and sometimes not the most important one. Cost is real. So is travel. So is the question of how much time you can take afterward to actually let the experience land. A weekend session jammed between two stressful work weeks is a waste of money and an unkindness to yourself. I've sat across from a lot of people considering their first psychedelic retreat. The ones who tend to do well aren't the bravest or the most spiritually fluent. They're the ones who know why they're going. Not in a grand way — just specifically. “I want to look at what happened with my father.” “I want to know if I can stop drinking.” “I've been depressed for three years and nothing has moved.” A clear question makes for clearer work. The ones who struggle are usually running from something rather than toward something, or they've heard psilocybin called a miracle and they want the miracle. The medicine doesn't reward that posture. It tends to show people exactly what they've been avoiding, which is rarely comfortable and almost always useful in the long run. Oregon's experiment is still young. The price point will likely come down as more centers open and competition grows. The model itself — supervised, integrated, deliberately slow — is probably closer to what responsible psychedelic care looks like than either the underground or the pharma-clinical-trial extremes. Whether you go that route, choose a traditional ayahuasca retreat abroad, or stay home and read a few more books before deciding, the honest move is the same: get specific about what you want, get honest about your medical realities, and don't outsource the decision to a marketing brochure. If something here is sitting with you and you want to look at concrete options, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with it. The retreat will still be there next month, and the question of whether you're ready is worth more than a quick yes.
How Psychedelics Reshape the Brain: New Science on Depression and Healing
For a long time, the story we were told about depression was tidy and chemical. Your serotonin is low. Take this pill. Wait six weeks. Feel better. Except for millions of people, that script never quite worked — and the more neuroscientists look under the hood, the messier the actual picture becomes. Depression, it turns out, isn’t just a chemistry problem. It’s a structural one. And psychedelics, of all things, may be one of the most interesting tools we have for addressing it. That’s not a wellness-influencer claim. It’s where the lab work is pointing. Researchers studying psychedelics — LSD, psilocybin from magic mushrooms, DMT from ayahuasca, MDMA — have found that these compounds don’t just shift perception for a few hours. They appear to physically change the architecture of neurons themselves. And those changes look a lot like the opposite of what depression does to the brain. If you picture a neuron as a tree, its dendrites are the big branches reaching out toward other cells, and the tiny dendritic spines are the smaller offshoots that catch incoming signals. Neuroscientists genuinely borrow horticultural language for this — arbors, pruning, growth. The brain is, in a real sense, a forest that thins and thickens depending on how you live in it. In people with chronic depression, certain regions of that forest go quiet. The prefrontal cortex — the area that helps regulate mood, anxiety, and decision-making — shows atrophy. Branches shrivel. Spines disappear. Connections that used to fire together fall out of contact. This shrinkage correlates with the experience people describe in plain language: feeling flat, disconnected, locked in, unable to imagine anything different. The old chemical-imbalance story doesn’t really account for any of this. It treated the brain like a soup that needed reseasoning. What the structural research suggests is closer to a garden that’s been neglected through a long drought. You don’t fix a drought by adjusting one ingredient. You have to bring the system back to life. Here’s where it gets interesting. When researchers grow neurons in a dish and expose them to psychedelic compounds, the neurons sprout. More branches. More spines. More synaptic connections with neighboring cells. The same thing shows up in studies on fruit flies and rodents. The effect is fast — sometimes within 24 hours — and it lasts. Scientists have started calling these compounds psychoplastogens: substances that rapidly promote structural plasticity in the brain. The category includes the classic psychedelics (LSD, psilocybin, DMT), MDMA, and ketamine, which technically isn’t a psychedelic at all but produces eerily similar effects on neuronal growth. They appear to work, at least in part, by activating a protein called mTOR, which acts as a kind of master switch for cell growth. This matters because the brain changes don’t expire when the trip ends. The hallucinatory part of an ayahuasca night might last six or eight hours. The neural rewiring it kicks off seems to keep working for weeks. That timeline lines up with what people consistently report after well-held ceremonies — that the days and months afterward are when the real shifts happen, not the night itself. Ayahuasca is the most studied plant medicine in this space, partly because traditional Amazonian use has been documented for so long and partly because DMT — the active visionary alkaloid — is one of the more dramatic psychoplastogens in the lineup. A 2015 Brazilian study found that a single dose of ayahuasca produced fast-acting antidepressant effects within a day in patients with treatment-resistant depression. Not modest improvements over months. Same-day shifts. The Amazonian curanderos who work with ayahuasca, San Pedro, and other master plants would tell you none of this is news. They’ve been describing these medicines as plant teachers for generations — beings that show you what’s stuck, what needs tending, what wants to grow. The Western science just gives us a different vocabulary for the same observation: something about these compounds wakes the brain back up. It’s worth being honest, though. The lab data is exciting; it isn’t a guarantee. A neuron sprouting in a dish is not the same as a human being healing from twenty years of trauma. The ceremonial container, the integration afterward, the people you sit with — all of that matters enormously for whether the biological window the medicine opens turns into actual change. The same structural logic applies to addiction. Addictive behavior carves deep ruts in the brain — strong, well-worn neural circuits that fire reliably in response to certain cues. Conventional treatment tries to weaken those circuits gradually, through behavior change and abstinence. It works, but slowly, and relapse rates are brutal. Psychedelic-assisted recovery seems to work differently. By temporarily destabilizing the brain’s rigid patterns and encouraging new growth, plant medicines may give a person something closer to a window — a period where the old grooves loosen enough for new ones to form. Ibogaine, in particular, has shown striking results for opioid addiction. Ayahuasca and psilocybin have shown promise for alcohol dependence and tobacco cessation. MDMA-assisted therapy for PTSD is moving toward approval in several jurisdictions. None of this means you swallow a substance and your addiction lifts. The substance opens a door. Walking through it — with a skilled facilitator, a real preparation period, and a serious integration practice — is what does the work. The brain’s new growth needs somewhere to grow toward. Here’s the part the enthusiastic articles tend to gloss. Promoting rapid neural growth is a powerful intervention, and we don’t fully understand its long-term consequences. Excessive mTOR activity has been linked to other conditions, including some neurodevelopmental disorders. The same biological mechanism that may heal one brain in one context might do something else entirely in another. There are also the obvious considerations: And the experience itself isn’t gentle. Ayahuasca nights routinely involve purging, hours of intense visionary content, and moments most people would describe as the hardest thing they’ve ever done. The brain’s sudden plasticity is not a soft, fuzzy event. It’s a system being shaken loose. If you’ve read this far, you’re probably not casually curious. Most people researching plant medicine seriously are doing it because something in their life hasn’t shifted through the usual channels — therapy, medication, willpower, time. That’s a legitimate reason to look, but it also means the decision deserves more care than choosing a vacation. A few honest questions worth sitting with before booking anything: Cost varies wildly. A reputable ayahuasca retreat in Peru typically runs between $1,500 and $3,500 for a week, with luxury operations going much higher. Ibogaine clinics, because they require medical supervision, tend to start around $5,000 and climb. Cheaper isn’t always worse and expensive isn’t always better — what matters is the integrity of the people holding the space. The most ambitious researchers in this field are trying to engineer compounds that produce the neural growth without the hallucinations — a kind of psychoplastogen without the visionary night. Whether that’s desirable or whether it misses the point is one of the live debates in the space. Plenty of clinicians and traditional practitioners would argue that the subjective experience isn’t a side effect to be optimized away. It’s where the meaning gets made. For now, the practical situation is this: legal access to psychedelics is expanding (Oregon and Colorado have decriminalized or regulated psilocybin services; ayahuasca remains legal in Peru, Brazil, Costa Rica, and a handful of other places), the research keeps stacking up, and more people every year are deciding the risks of trying are smaller than the costs of staying stuck. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, treat it as a decision, not a leap. The brain is more plastic than we used to think. So is a life.
Inside Oregon's Legal Psilocybin Experiment: What It Means for Psychedelic Retreats
Something quietly historic is happening in Oregon. While most of the United States still treats psilocybin mushrooms as a Schedule I substance, this one state on the Pacific coast is busy building the country's first legal, regulated framework for psilocybin services. Not decriminalisation. Not a research carve-out. An actual, licensed system where adults can sit with psilocybin under the care of a trained facilitator. For anyone weighing a psychedelic retreat — especially folks who've been reading about psilocybin for depression, end-of-life anxiety, or stubborn patterns that no amount of talk therapy has shifted — Oregon matters. It's the closest thing we have to a working blueprint. And the people building it are doing so in real time, in public, with all the messiness that involves. Back in 2020, voters passed Measure 109, the ballot initiative that authorised the creation of a legal psilocybin services program. It didn't legalise mushrooms in the supermarket sense. What it did was open a narrow but very real door: adults aged 21 and over could, eventually, consume psilocybin at licensed service centres under the supervision of trained facilitators. No prescription required. No specific diagnosis required. That last part is what makes the Oregon model genuinely novel. Other psychedelic pathways being developed in the U.S. — MDMA for PTSD, psilocybin for treatment-resistant depression — are medical models, gated by diagnosis and FDA approval. Oregon's program is a services model. The state regulates training, product, and venues, but the experience itself sits closer to a ceremony than a clinic visit. That distinction matters more than it first appears. Two main bodies have done the heavy lifting. The Oregon Psilocybin Advisory Board drafted recommendations covering everything from facilitator training requirements to product testing standards. The Oregon Health Authority, through its Oregon Psilocybin Services division, turned those recommendations into actual rules. The first legal sessions began taking place in 2023, and the program has been expanding — and learning hard lessons — ever since. A program like this doesn't appear out of nowhere. It's the product of a small, identifiable group of people — campaign organisers, attorneys, regulators, therapists, and entrepreneurs — who spent years pushing the boulder up the hill. A few names worth knowing if you're trying to understand how this market actually works. Tom Eckert and the late Sheri Eckert were the chief petitioners behind Measure 109. Tom went on to chair the advisory board during the early rulemaking, then stepped away amid questions about board-member conflicts of interest — an early reminder that this industry has the same political mess as any other. He now directs work at InnerTrek, one of the larger psilocybin-facilitator training programs in the state, and at the Sheri Eckert Foundation, which funds scholarships for people who want to train as facilitators but can't afford the tuition. Sam Chapman managed the Measure 109 campaign and now leads the Healing Advocacy Fund, a nonprofit that's stayed deeply involved in implementation. David Bronner — yes, the soap guy — poured roughly $2 million of Dr. Bronner's money into passing the measure and has continued funding training programs, harm-reduction work, and equity initiatives. His company has put tens of millions into drug-policy reform over the years, which is not the kind of detail you forget once you've seen it on a bottle of peppermint castile. On the regulatory side, André Ourso and Angela Allbee at the Oregon Health Authority have been the people actually translating a ballot measure into a working program. Ourso previously oversaw the rollout of Oregon's cannabis market, which gave the state at least some institutional muscle memory for standing up a regulated controlled-substance industry. Allbee manages day-to-day operations of Oregon Psilocybin Services, which is the part of state government that issues the licences and writes the rules. One of the most interesting fights inside Oregon's program has been about facilitators — who they are, how they're trained, and how much it costs to become one. This isn't a side debate. It's the whole ball game. Jon Dennis, an attorney and cofounder of the Entheogenic Practitioners Council of Oregon, has been a persistent voice arguing that religious, spiritual, and community-based practitioners should have a meaningful role in the legal program. His worry — and it's a reasonable one — is that if facilitator training is structured like a graduate degree, with the price tag to match, the only people serving clients will be affluent therapists, and the cost of a session will price out the people who most need access. Angela Carter, a vice chair on the advisory board, has pushed similar equity and harm-reduction priorities from inside the regulatory process. At the same time, organisations like Fluence — cofounded by Ingmar Gorman and Elizabeth Nielson, both psychologists who worked on MDMA-assisted therapy trials — have been building rigorous clinical-style training programs aimed at therapists who want to add psilocybin work to their practice. Both visions are defensible. Both are getting built. How they coexist will shape what an Oregon psilocybin session actually feels like. Here's the practical takeaway for someone in the research phase. Oregon's legal program is not a retreat in the Costa Rica or Peruvian-jungle sense. Most licensed service centres offer a single session — preparation meeting, dosing day, integration meeting — rather than a multi-day immersive experience. Prices have settled in the rough neighbourhood of $1,000 to $3,500 for the full arc, depending on the facilitator, the venue, and the dose. That's lower than some international retreats and considerably higher than others. If you're weighing your options, a few honest things worth holding in mind: Colorado followed Oregon's lead with its own psychedelic-services initiative, passed in 2022 and now rolling out. Other states are watching closely, drafting bills, and quietly preparing legislation. The federal picture remains murky — psilocybin is still Schedule I, and the DEA hasn't softened its public stance — but the state-level momentum is real, and it's not slowing down. What Oregon proves, more than anything, is that a regulated psychedelic services market is possible. Not easy. Not without its conflicts of interest, equity gaps, and growing pains. But possible. For readers who've spent years assuming plant medicine meant flying to South America or knowing the right underground guide, that's a meaningful shift. It's also worth saying plainly: a legal framework doesn't make psilocybin right for everyone. People on certain antidepressants, people with personal or family histories of psychosis, people in acute crisis — these are situations where a thoughtful provider will tell you to wait, or to look at other tools first. The most useful question isn't where to do this work but whether now is the time, and with what kind of support around you. If you're somewhere in that weighing phase, it can help to see what's actually on offer — different settings, different traditions, different price points — before committing to anything. A curated set of psilocybin and plant-medicine retreats can be browsed on our marketplace here, which is a low-pressure way to compare what's out there while you keep doing your homework. Oregon's experiment is young. The facilitators are still learning. The regulators are still adjusting. But the door is open in a way it wasn't five years ago, and the people who pushed it open deserve some credit for that — even when the politics behind the scenes have been less than tidy.
Ketamine for Depression: What the Latest Trial Results Mean
Ketamine, a medication primarily used as an anesthetic, has been explored as a potential treatment for severe forms of depression. Its fast-acting nature makes it an attractive option for patients experiencing sudden bouts of suicidality. However, the latest trial results from Atai Life Sciences, a leading company in the field of psychedelics, have raised questions about its efficacy. The trial, conducted by Perception Neuroscience, a subsidiary of Atai, involved 102 patients with treatment-resistant depression. These patients were administered either a 60mg dose of PCN-101, a 30mg dose, or a placebo. The results showed that patients who received the 60mg dose did not experience significant improvement in their depression symptoms compared to those who received the placebo. This outcome is particularly noteworthy given the current landscape of depression treatment. With many patients not responding to traditional therapies, the search for alternative treatments is urgent. Ketamine, with its unique mechanism of action, had been seen as a promising candidate. The failure of this trial, however, underscores the complexity of treating depression and the need for continued research. The trial's methodology involved administering the drug intravenously and then assessing the patients' depression symptoms 24 hours later using the Montgomery-Åsberg Depression Rating Scale. The lack of significant improvement in the treatment group compared to the placebo group is a critical finding. It suggests that, at least in the context of this study, ketamine may not offer the therapeutic benefits that were hoped for. The implications of this trial are multifaceted. For patients and their families, the news may be disappointing, especially for those who have been waiting for new treatment options. For the field of psychedelic research, this trial serves as a reminder of the challenges involved in developing effective treatments. It highlights the need for rigorous scientific testing and the importance of not overstepping the bounds of current evidence. Atai Life Sciences has announced plans to continue reviewing the data from the trial to determine the next steps. This approach is prudent, given the potential that subgroup analyses or further research could uncover beneficial effects that were not immediately apparent. Ketamine is not the only psychedelic compound being explored for its therapeutic potential. Psilocybin, the active ingredient in magic mushrooms, and MDMA, commonly known as ecstasy, are also under investigation for their possible roles in treating mental health disorders. The journey of these substances from recreational drugs to potential therapeutic agents is a complex one, marked by both promise and challenge. The approval of Spravato, a drug based on ketamine, by the FDA in 2019 for the treatment of severe depression, marked a significant milestone in this journey. It demonstrated that, with rigorous testing and regulatory approval, psychedelic-derived medicines could enter the mainstream of psychiatric treatment. However, the path forward is not without its obstacles. Regulatory hurdles, public perception, and the need for high-quality clinical trials are just a few of the challenges that must be overcome. The recent trial results, while disappointing, are a part of this process. They contribute to the growing body of evidence that will eventually guide the development and use of psychedelic medicines. The latest trial results on ketamine's effectiveness in treating depression are a sobering reminder of the complexities and challenges inherent in psychiatric research. While they may dampen some of the enthusiasm surrounding psychedelic medicine, they do not diminish the potential that these substances hold. Instead, they underscore the importance of a cautious, evidence-based approach to developing new treatments. As the field of psychedelic medicine continues to evolve, it is crucial that researchers, clinicians, and patients remain committed to the principles of rigorous scientific inquiry and patient safety. The future of psychedelic medicine is promising, but it must be built on a foundation of solid evidence and careful consideration of both the benefits and the risks of these powerful substances.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
